Telomir Pharmaceuticals, Inc. TELO
Set alert
0.94 USD -0.03 -3.01%
At close · Oct 30
0.92 -0.02 -1.76%
After hours · Oct 30, 4:00 PM ET
0.7905 Day range 0.9899
0.919 52-week range 1.56
- YTD
- -29.68%
- 1 year
- -37.65%
- Open
- 0.96
- Prev close
- 0.9642
- Mkt cap
- 68.90M
- Vol
- 96.70K
- Avg vol
- 84.05K
- EPS
- -1.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7905
- High
- 0.9899
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 5.77
- Inst. own
- 6.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 4.61
- 200-d avg
- 5.36
- 1y target
- 12.15
2Y chart
Events in this range
- Nov 12, 2024Earnings: -0.2; estimate 0; surprise —%
Signals (95)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 27, 2026 | 3 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 30, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 9, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 6, 2026 | 7 months ago |
| SMA: Bullish | Mar 3, 2026 | 8 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| RSI: Oversold | Jan 30, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 9, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 12, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 21, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 19, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 22, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| RSI: Overbought | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 11, 2025 | 1 year ago |
| RSI: Oversold | Sep 2, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 18, 2025 | 1 year ago |
| RSI: Overbought | Jul 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 15, 2025 | 1 year ago |
| RSI: Oversold | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bearish | Mar 17, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| SMA: Bearish | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
| RSI: Overbought | Dec 6, 2024 | 1 year ago |
Key statistics
- Market cap
- 138.65M
- Enterprise value
- 152.64M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 310.67
- EPS (TTM)
- -0.77
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 213.65K
- Total cash
- 834.64K
- Total debt
- 93.43K
- Return on equity
- -1752.69%
- Shares outstanding
- 29.75M
- Short % of float
- 3.89%
- 50-day average
- 4.61
- 200-day average
- 5.36
Analyst view
Consensus: none
Price target (mean) 12.15
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.05.
Financials — quick view
TELO Revenue — quarterly 0
TELO Net income — quarterly -1.72M
TELO EPS — quarterly -0.79
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.20 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.05 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.23 | — | — |
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- telomirpharma.com
News
- TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
- Telomir Pharmaceuticals Announces ~$5.6M Investment In PIPE Financing Through Common Stock Issuance
- Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
- Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4
- Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
- Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models
- Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Your note
Sign in to keep a note on TELO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAY SHORE TRUST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.89% | 1,151,527 | 5.37M | Sep 29, 2024 |
| Blackrock Inc. | 1.24% | 366,878 | 1.71M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 238,737 | 1.11M | Sep 29, 2024 |
| Suncoast Equity Management | 0.17% | 51,194 | 238.56K | Sep 29, 2024 |
| Bank Of New York Mellon Corporation | 0.17% | 51,364 | 239.36K | Sep 29, 2024 |
| Northern Trust Corporation | 0.16% | 48,680 | 226.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 834,700 | 3.89M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 261,970 | 1.22M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 93,887 | 437.51K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.17% | 49,772 | 231.94K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 30,433 | 141.82K | Oct 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.10% | 28,721 | 133.84K | Oct 30, 2024 |